New combo therapy aims to stop mesothelioma return after surgery

NCT ID NCT05932199

Recruiting now Disease control Sponsor: Baylor College of Medicine Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether giving immunotherapy drugs (durvalumab and tremelimumab) alone or with chemotherapy before surgery can help prevent pleural mesothelioma from coming back. About 52 people with potentially removable tumors will take part. The main goal is to see if more than 60% of patients stay cancer-free for at least one year after treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: durvalumab and tremelimumab (immunotherapy drugs) with or without chemotherapy (cisplatin or carboplatin plus pemetrexed)
What this could lead to: If successful, this could offer a new treatment option that delays cancer return after surgery for people with pleural mesothelioma.
What could go wrong: This is an early-phase trial with only 52 participants, so results may not apply to everyone. Immunotherapy can cause serious side effects like inflammation of organs.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MALIGNANT PLEURAL MESOTHELIOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

malignant pleural mesothelioma mesothelioma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MESOTHELIOMA

Contacts and locations

Locations

Baylor St Lukes
RECRUITING

Houston, Texas, 77030, United States
Duke Cancer Institute
NOT_YET_RECRUITING

Durham, North Carolina, 27710, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.